跳至主要内容
临床试验/EUCTR2016-004952-30-Outside-EU/EEA
EUCTR2016-004952-30-Outside-EU/EEA进行中(未招募)1 期

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients

Eisai Co, Ltd.0 个研究点目标入组 58 人开始时间: 2017年2月13日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
58

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Participants who are diagnosed as LSG with tonic/atonic seizures and atypical absence seizures (A history of atypical absence seizures will also be incorporated).
  • 2. Participants who had a slow spike-and-wave pattern in an electroencephalogram within 6 months prior to the enrollment for the Observation Period.
  • 3. Participants who had at least a total of 90 seizures in the 28 days prior to the enrollment for the Observation Period.
  • 4. Participants who have been on 1 - 3 anti-epileptic drugs from 28 days prior to the enrollment for the Observation Period and have not changed the type of the anti-epileptic drugs.
  • 5. Participants who have not changed the type nor the dose or administration of the anti-epileptic drugs they are taking in the Observation Period.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 35
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 23
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Participants who had a history of generalized tonic-clonic status epilepticus within baseline.
  • 2. Participants who received drug therapy at least 4 times to be rescued from status epilepticus within baseline.
  • 3. Participants who had a history of hypoxia which needed emergency resuscitation within 12 months prior to the Treatment Period.
  • 4. Participants who were on a ketogenic diet or have received adrenocorticotropic hormone (ACTH) therapy or Vitamin B6 therapy within 6 months prior to the Treatment Period.
  • 5. Participants who had a history of suicide attempt within the 1 year prior to the Treatment Period.
  • 6. Participants who had a history of or has an allergy to triazole compound.
  • 7. Participants who have clinically significant electrocardiogram abnormalities at baseline.
  • 8. Participants who are pregnant, who may be pregnant, who are lactating or who wish to be pregnant.

研究者

发起方
Eisai Co, Ltd.

相似试验